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ABSTRACT 
Hao Zhang 
 
Mechanisms of Cytoskeletal Dysregulation in the Kidney Proximal Tubule During ATP 
Depletion and Ischemia 
 
Knowledge of the molecular and cellular mechanisms of ischemic injury is 
necessary for understanding acute kidney injury and devising optimal treatment regimens.  
The cortical actin cytoskeleton in the proximal tubule epithelial cells of the kidney 
nephron, playing an important role in both the establishment and maintenance of cell 
polarity, is drastically disrupted by the onset of ischemia.  We found that in LLC-PK cells 
(a porcine kidney proximal tubule epithelial cell line), cortactin, an important regulator of 
actin assembly and organization, translocated from the cell cortex to the cytoplasmic 
regions upon ischemia/ATP-depletion.  Meanwhile both the tyrosine phosphorylation 
level of cortactin and cortactin’s interaction with either F-actin or the actin nucleator 
Arp2/3 complex were down-regulated upon ischemia/ATP-depletion or inhibition of Src 
kinase activity.  These results suggest that tyrosine phosphorylation plays an important 
role in regulating cortactin’s cellular function and localization in the scenario of kidney 
ischemia.  The Rho GTPase signaling pathways is also a critical mediator of the effects of 
ATP depletion and ischemia on the actin cytoskeleton, but the mechanism by which ATP 
depletion leads to altered RhoA and Rac1 activity is unknown.  We propose that ischemia 
and ATP depletion result in activation of AMP-activated protein kinase (AMPK) and that 
this affects Rho GTPase activity and cytoskeletal organization (possibly via TSC1/2 
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complex and/or mTOR complex).  We found that AMPK was rapidly activated (≤ 5 
minutes) by ATP depletion in S3 epithelial cells derived from the proximal tubule in 
mouse kidney, and there was a corresponding decrease in RhoA and Rac1 activity.  
During graded ATP-depletion, we found intermediate levels of AMPK activity at the 
intermediate ATP levels, and that the activity of RhoA and Rac1 activity correlated 
inversely with the activity of AMPK.  Activation of AMPK using two different drugs 
suppressed RhoA activity, and also led to morphological changes of stress fibers.  In 
addition, the inhibition of AMPK activation partially rescued the disruption of stress 
fibers caused by ATP-depletion.  This evidence supports our hypothesis that the 
activation of AMPK is upstream of the signaling pathways that eventually lead to RhoA 
inactivation and cytoskeletal dysregulation during ATP-depletion. 
 
                                                                                             Simon J. Atkinson Ph.D., Chair 
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CHAPTER I 
 
Introduction 
 
Cellular injuries during ischemia 
Ischemic acute renal injury (ARI) remains the leading cause of renal failure in 
adults [1]. Understanding the cellular consequences of ischemic injury is necessary for 
devising optimal treatment regimens for ARI. 
The basic structural and functional unit of the kidney is the nephron. The 
glomerulus of the nephron delivers a plasma ultra-filtrate to the proximal tubule, which 
selectively secretes and reabsorbs a variety of substances in the process of making urine. 
The proximal tubule of the nephron reabsorbs about 60% of the ultrafiltrate delivered 
from the glomerulus before passing the filtrate on sequentially to the descending limb, 
loop and ascending limb of Henle, the distal tubule and finally the collecting duct [2].  
The proximal tubule epithelium is the most susceptible to low oxygen tension among all 
the tissues of the nephron.  After an ischemic insult, some cells of the proximal tubule 
epithelium lose polarity, become necrotic or undergo apoptosis. The damaged cells 
slough-off into the lumen forming an intratubular cast. With recovery, some of the 
remaining epithelia depolarize, divide, migrate to vacant locations along the tubule and 
repolarize into functional epithelium [3-6]. 
The epithelial cells lining the proximal tubule lumen possess highly polarized 
apical (facing the urinary lumen) and basolateral surface membrane domains that have 
distinctly different lipid and protein compositions [7].  The main structures of the apical 
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membrane domain include the terminal web and the brush border, and the brush border 
can be divided into microvilli. Within each microvillus are 20-30 longitudinally oriented, 
polarized actin microfilaments that extend into, and are stabilized in the terminal web 
region by interaction with different proteins.  There is a dense meshwork of actin and 
associated proteins as well as intermediate filaments in the terminal web.  These 
meshwork structures are oriented primarily perpendicular to the microvilli [8, 9]. 
The proximal tubule has a high rate of endocytic activity at the apical membrane.  
There are different kinds of receptors enriched at the apical membrane [10-12].  Sodium 
(Na+) reabsorption is one of the key functions of the proximal tubule.  Such sodium 
reabsorption is dependent upon both the polarized delivery of specific carrier proteins 
such as the Na+ transporter and the Na+-dependent cotransporter to the apical membrane 
and the localization of the Na+, K+-ATPase to the basolateral membrane [13, 14].  Many 
receptors on the apical membrane are in a constant process of endocytosis/internalization 
and/or eventually being recycled back to the apical surface [15, 16].  The actin and 
microtubule cytoskeleton play critical roles for efficient and accurate targeting and 
delivery of these receptors in their recycling pathways [10, 17-19].  The basolateral 
membrane is structurally separated from the apical by junctional complexes which are 
critical for establishing and maintaining structural and functional cell polarity, as well as 
for the formation of a protein channel between the adjacent cells for the passage of low 
molecular weight proteins [13, 20].  The basal portion of the cells is attached to the 
substratum via hemidesmosomes mediated by integrins.  Focal adhesions are also present 
on the basal surface membrane and help anchoring cells to the substratum [13, 21]. 
 
3 
The apical and basolateral membrane polarity is critical for the normal filtration 
function of the proximal tubule, and the loss of such a membrane polarity is the hallmark 
 
Figure 1.  Cellular injuries in proximal tubule epithelia after ischemia 
  
Fig. 1. During ischemia multiple cellular injuries including actin cytoskeleton disruption 
occur in proximal tubule epithelial cells (see text for details).  Adapted from Wagner et al. 
1999 Pediatric Nephrology 13(2):163-170 
 
of cellular injury caused by ischemia [22-24] (Fig. 1).  The onset of ischemia rapidly 
induces distinctive and rapid disruption of microvilli of apical brush border in proximal 
tubule epithelia, with the extent of such disruptions being dependent on the severity of 
ischemia [5, 25].  During microvilli disruptions induced by ischemia, the microvillar 
actin core disassembles [26, 27].  Meanwhile, either concurrently or subsequently, 
microvillar membranes either internalize into the cell’s cytosol or are shed into the tubule 
lumen as blebs [5].  In parallel with apical membrane structural changes, basolateral 
membrane changes also occur during ischemia.  One example is that many surface 
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basolateral membrane proteins will be untethered or redistributed, contributing to the loss 
of cell-substrate and cell-cell adhesion [28-31].  Meanwhile the junctional complexes in 
proximal tubule epithelial cells are also disrupted by ischemia, which contributes to the 
loss of cell polarity [32, 33]. 
The cortical actin cytoskeleton plays a critical role in terms of establishing and 
maintaining the apical and basolateral membrane polarity, therefore its disruption to a 
significant extent precedes the membrane changes during ischemia [26, 27, 34].  During 
kidney ischemia there are two fundamental components of the actin cytoskeletal 
alterations that are observed; the first is the breakdown of actin filament-containing 
structures including microvillar actin bundles and stress fibers, with the actin they contain 
being re-distributed to other regions of the cell [26, 35]; the second is the unregulated 
polymerization of G-actin (unpolymerized actin monomers) so that the net fraction of F-
actin increases with ischemia and ATP depletion and the monomer pool necessary for 
maintenance of normal dynamic actin structures is depleted [35, 36].  This global 
dysregulation of the cytoskeleton in the setting of increased F-actin implies a complex 
effect that not only impinges directly on the biochemistry of actin polymerization, but 
also affects higher order assembly of actin filaments into structures such as bundles and 
stress fibers.  The most likely explanation for the latter effects is that signaling pathways 
regulating the actin cytoskeleton are affected by ATP depletion and ischemia, so that the 
mechanisms that normally integrate actin function become the mediators of its 
dysregulation instead.  Therefore the study of these upstream signaling pathways 
regulating the actin cytoskeleton is particularly important for us to understand the 
molecular mechanisms of kidney ischemic injury. 
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On the other hand, ischemic injury also disrupts the localization of apical and 
basolateral membrane components, for example the normally basolateral Na+, K+-ATPase 
translocates to the apical membrane, apical leucine aminopeptidase to the basolateral 
membrane, while ischemia duration-dependent alterations in apical and basolateral 
membrane lipids also occur [22, 35, 37, 38].  The correct targeting of protein components 
of the apical and basolateral membranes to surface membrane destinations after synthesis 
at ER, modification at and transportation from Golgi; as well as their recycling from 
surface membrane in clathrin-coated vesicles by endocytosis and then recycling back to 
the original surface membrane domains, or transcytosis to particular surface membrane 
domains for enrichment; all these processes are very important for establishing and 
maintaining apical and basolateral membrane polarity, and also important for the proper 
filtration function of the proximal tubule, therefore they could be disrupted by ischemia 
too [13, 39, 40].  Investigating the regulation of proteins that play important roles in these 
processes mentioned above will certainly advance our knowledge of ischemic acute renal 
failure and consequently assist our search for optimal treatments. 
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CHAPTER II 
 
Decrease of Cortactin Tyrosine Phosphorylation during ATP-Depletion in a Cell 
Culture Model of Ischemic Renal Injury and Its Effect on Cortactin’s Cellular 
Function  
 
1.  Introduction 
Cortactin 
Cortactin is an 80/85kDa (both vertebrate and invertebrate cortactin migrate as a 
doublet separated by 5kDa upon SDS-PAGE) protein expressed in all types of eukaryotic 
cells.  It contributes to the epithelial cell phenotype as an important regulator of actin 
assembly and organization [41].   Cortactin was initially discovered in v-Src-transformed 
chicken embryo cells as a tyrosine phosphorylation substrate of Src, and it co-localized 
with F-actin in the peripheral extensions of normal cells and podosomes (rosettes) after v-
Src transformation [42].  It was later discovered to bind F-actin directly and was enriched 
in cortical structures such as membrane ruffles and lamellipodia in different adherent cell 
types [43].  So far cortactin has been discovered to localize to dynamic actin cytoskeleton 
at multiple cellular locations and to be involved in many kinds of cellular functions.  It 
localizes to growth cones of cultured neurons [44]; it was found to associate with 
endosomal vesicles in fibroblast cells [45], and its overexpression was found to enhance 
the motility of fibroblasts [46]; it binds directly and co-localizes with Drosophila cell-cell 
tight junction component ZO-1 [47]; it is recruited to cell-cell adherens junctions in 
response to homophilic E-cadherin ligation and inhibition of cortactin activity perturbs 
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both cell morphology and junctional accumulation of cadherin in polarized MDCK 
epithelial cells [48].  In addition to regulating the actin cytoskeleton, cortactin is also a 
component of clathrin-coated pits and inhibition of its activity disrupts both clathrin-
dependent and clathrin-independent receptor-mediated endocytosis [49-51]; it was also 
found to localize to the Golgi apparatus and play an important role in post-Golgi transport 
[52].  On the other hand, cortactin and/or its triggering of actin polymerization were 
found to be important to the invasion of pathogens in different cell types [53, 54].  
Meanwhile the human homologue of cortactin, the EMS1 gene, its amplification and 
overexpression were found in human carcinomas [55, 56]; overexpression of cortactin 
was also found to enhance significantly bone metastasis of breast cancer cells [57], and it 
was also found to be essential for the formation of invadopodia and subsequent 
extracellular matrix degradation in metastatic cancer cells [58, 59].  Therefore cortactin is 
also a protein of great interest to oncologists. Finally in immunohistochemistry study 
cortactin was found to stain the brush border / terminal web region of human kidney [60]. 
The N-terminal region of cortactin’s total length of approximately 90 amino acids 
is designated the amino terminal acidic domain (NTA) (Fig. 2).  It binds directly with 
Arp2/3 complex, the actin nucleator.  Following the NTA domain are six and a half 
tandem copies of a 37 amino acid repeat.  The tandem repeat four is necessary for 
cortactin to bind F-actin stably [61].  Cortactin binds with both F-actin and Arp2/3 
complex by itself or in synergy with other actin nucleation promotion factors, for 
example N-WASP, and subsequently stimulates Arp2/3 complex’s actin nucleation 
activity which initiates the “branching-out” from the side of existing F-actin filament to 
build up an actin network [62, 63].  The tandem repeats are followed by an α-helical 
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domain of approximately 50 amino acids, which is a less well-conserved region rich in 
proline, serine and threonine residues, and then finally a C-terminal SH3 domain.  The 
SH3 domain of cortactin binds with multiple partners, for example the proline-rich 
domain of dynamin-II [64]; N-WASP and WASP [65]; WIP (WASP-interacting protein) 
which is involved in filopodia formation [66]. 
 
Figure 2.  Cortactin structural domains 
 
Fig. 2. The structural domains of cortactin and the interactions of cortactin with other 
proteins at different domains (see text for details). 
 
Cortactin has always been considered as an important regulator of the actin 
cytoskeleton, and has been found to participate in multiple cellular functions, although 
our knowledge of regulatory mechanisms controlling its activity and localization is still 
very incomplete and sometimes even contradictory.  One mechanism that is of great 
interest to investigators is the phosphorylation of cortactin at multiple sites by different 
kinases including Src.  Three tyrosine residues, Tyr-421, 466 and 482, have been 
identified as the target phosphorylation sites of Src [67].  Cortactin was also reported to 
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be tyrosine-phosphorylated by Fyn/Fer kinase [68, 69]; meanwhile, Syk, another Src 
family kinase, also binds with and tyrosine-phosphorylates cortactin in platelets upon 
thrombopoietin stimulation [70].  Two serine residues (Ser-405, Ser-418) in the proline-
rich domain are phosphorylated by Erks in vitro and possibly also in vivo in HEK 293 
cells treated with epidermal growth factor [71].  In addition to the phosphorylation sites 
mentioned above, 17 new sites were reported recently in a study using mass spectrometry 
[72].  Most recently cortactin was reported to be an in vivo substrate of protein kinase D 
(PKD) on Ser298 and Ser348, although no effect was found on cortactin’s cellular 
function and localization by PKD phosphorylation on these target sites yet [73]. 
Extensive studies have been done on tyrosine-phosphorylation of cortactin and its 
functional consequences, although we still do not know how tyrosine-phosphorylation 
regulates cortactin’s function exactly.  It was reported that tyrosine-phosphorylated 
cortactin is enriched in lamellipodia of fibroblasts [74], and yet cortactin’s translocation 
to the cell periphery does not depend on tyrosine phosphorylation in COS7 cells [75]; 
tyrosine phosphorylation of cortactin has been shown to be important to migration of 
endothelial cells [67], while an in vitro assay shows that it down-regulates cortactin’s 
actin-filament cross-linking ability [76]; tyrosine phosphorylation terminates cortactin’s 
activation of N-WASP and WASP [65], on the other hand, it was also reported that in the 
presence of the adaptor protein Nck, the tyrosine phosphorylation of cortactin by Src 
greatly enhanced Arp2/3 complex-mediated actin polymerization in vitro, which was 
further enhanced by the addition of N-WASP and WIP (WASP-interacting protein) [77].  
Phosphorylation of cortactin by Src was found to be important for podosome formation in 
osteoclasts [78], and is essential for the functional invadopodia formation in fibroblast 
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cells and human melanoma cells [79, 80].  Cortactin’s tyrosine phosphorylation was also 
reported to be involved in the regulation of endocytosis and ion channels [81-83], and 
src-mediated phosphorylation of cortactin enhances its association with GTPase 
dynamin-2 as shown by in vitro study.  Cortactin’s phosphorylation on Tyr421 has been 
shown to be important to N-cadherin-mediated intercellular adhesion strength [84], and 
Fer-dependent tyrosine phosphorylation of cortactin promotes N-cadherin’s mobility and 
enhances N-cadherin-mediated intercellular adhesion strength [85].  During ischemia, 
tight junction integrity is compromised and intercellular adhesion strength is reduced [86], 
and N-cadherin expression is reduced during ischemia and proteolytic fragments appear 
[87], but the fate of cortactin during ischemia and with recovery is unknown yet. 
Therefore we were interested in determining whether the tyrosine phosphorylation 
of cortactin changed during kidney ischemia, and whether this change affected cortactin’s 
cellular localization and its interactions with other proteins, and finally how these 
changes were related to the global actin cytoskeleton dysregulation during kidney 
ischemia. 
 
Dynamin 
The SH-3 domain at the C-terminus of cortactin can bind with the proline-rich 
domain of multiple partners, one of which is dynamin [64].  Co-localizing with cortactin 
and/or actin structures at multiple cellular locations in vivo, dynamin influences actin 
nucleation by purified Arp2/3 complex and cortactin in vitro in a biphasic manner [49, 52, 
64, 88, 89].  Dynamin, a 100kDa GTPase, is an essential component of vesicle formation 
in receptor-mediated endocytosis, caveolae internalization and also vesicle traffic in and 
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out of the Golgi [90, 91].  Among the three major isoforms of dynamin, dynamin-II is the 
only one that is ubiquitously expressed in different mammalian cells [90].  Dynamin was 
initially discovered and presumed to be a mechanochemical enzyme mediating 
interaction between microtubules [92].  Since the discovery that the protein encoded by 
the gene shibire in Drosophila, whose mutant impairs vesicular traffic in endocytosis, is 
dynamin’s homologue [93], as well as that the amino acid sequence of dynamin contains 
a GTP-binding domain [94], one of the major focuses of dynamin research has been its 
function in endocytosis as a GTPase by acting either like a pinching-force generating 
molecular motor during GTP hydrolysis or a traditional regulatory GTPase working on 
downstream effectors (and which mechanism is true is still to be determined). 
Dynamin’s critical role in endocytosis was confirmed by expressing its mutant 
with GTP-binding domain being either defective or deleted in different cell lines.  The 
expression of such mutants significantly blocked receptor-mediated endocytosis via 
clathrin-coated pits [95-97].  Later on, dynamin was found to be involved in multiple 
aspects of intracellular transport.  Dynamin was found to localize on caveolae and its 
GTPase activity was critical to caveolae-mediated endocytosis in both endothelial and 
epithelial cells [98, 99].  Dynamin-II (the ubiquitously expressed isoform) is enriched on 
phagosomes, and overexpression of its GTP-binding defective mutant inhibits particle 
internalization in macrophages [100].  Dynamin-II was first found to localize on trans-
Golgi network in HepG2 cells [101], later on it was found that dynamin antibodies 
strongly labeled the Golgi complex in cultured fibroblasts and melanocytes [102]; 
overexpression of dynamin-I GTP-binding defective mutant was found to inhibit 
endosome to Golgi transport [103], while overexpression of the similar mutant of 
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dynamin-II disrupted Golgi structure and also inhibited protein secretion from the trans-
Golgi to the plasma membrane in epithelial cells [104, 105].  Dynamin is also involved in 
regulation of the actin cytoskeleton.  Dynamin was found to translocate from the 
cytoplasmic regions to membrane ruffles at the leading edge of fibroblasts upon growth 
factor stimulation, while overexpression of a dynamin-II mutant, which had the proline-
rich domain (which binds to SH3 domain of cortactin) truncated, in Clone 9 rat 
hepatocyte cells changed the cell shape from being discoid into being peculiarly 
elongated or moon-shaped [64]; dynamin was also reported to be important for 
lamellipodia formation and cell spreading [106].  Dynamin was found to localize on and 
play an important role for the formation of highly dynamic actin-containing adhesion 
structures, podosomes, in Rous sarcoma virus (RSV)-transformed fibroblasts and 
osteoclasts [107], while in invasive tumor cells dynamin also localizes in invadopodia 
and is essential for the degradation of extracellular matrix [108]. 
The three isoforms of dynamin all share the same domain structure (Fig. 3).  The 
N-terminus of dynamin is the GTP hydrolysis domain followed by a middle domain 
which lacks sequence homology to any known structural motif [90].  After the middle 
domain is the PH (Pleckstrin Homology) domain.  The PH domain of dynamin favors 
binding to PI(4,5)P2, which is crucial for dynamin’s membrane localization and also 
enhances its GTPase activity [109].  The PH domain is followed by the GTPase effector 
domain (GED).  GED is the GAP (GTPase activating protein) for dynamin itself.  
Phospholipase D was identified to be another GAP for dynamin, and phospholipase D’s 
GAP function for dynamin is important for EGFR endocytosis in HEK 293 cells [110]. 
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The C-terminus of dynamin is the PRD (proline-rich domain) which mediates the binding 
with multiple partners including cortactin. 
 
Figure 3.  Dynamin structural domains 
 
Fig. 3. The structural domains of dynamin and the interaction of dynamin with cortactin 
(see text for details). 
 
One of dynamin’s special features is its self-assembly by oligomerization which 
significantly stimulates its GTPase activity [111].  Under low salt conditions and without 
either any underlying support or the presence of any nucleotide, purified recombinant 
dynamin was found to assemble spontaneously in vitro into rings and stacks of 
interconnected rings, which were comparable in dimension to the “collars” observed at 
the necks of invaginated coated pits that accumulated at synaptic terminals in shibire flies 
(which have paralysis associated with the block of endocytosis) [112]; similar rings and 
spirals of dynamin also formed under physiological salt conditions when beryllium 
fluoride (or aluminum fluoride) and GDP (or GTPγS) were added into purified 
recombinant dynamin [113].  Purified recombinant dynamin was also demonstrated to 
bind to anionic phospholipid bilayers in the absence of other proteins or guanine 
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nucleotide to form helical tubular structure, and the addition of GTP caused constriction 
of such dynamin tubules and formation of numerous small vesicles [114].  Meanwhile it 
has also been demonstrated that strong binding of dynamin PH domain to lipid 
membranes requires self-assembly of dynamin by oligomerization [115].  GED has been 
confirmed to be essential for dynamin self-assembly which is critical for GED’s GAP 
activity and therefore GTP hydrolysis by dynamin [116]. 
Like cortactin, dynamin also directly binds with Src kinase [117].  Src-mediated 
tyrosine-phosphorylation of dynamin has been found to be important for both receptor-
mediated and non-receptor-mediated endocytosis in different cell lines [118-120].  The 
major tyrosine phosphorylation sites of dynamin by either Src or possibly other kinases in 
vivo have been identified to be Tyr-231 in the GTPase domain and Tyr-597 in PH domain 
for both dynamin-I and dynamin-II [118, 120].  Tyrosine phosphorylation of dynamin by 
Src was found to stimulate dynamin-I’s GTPase activity significantly and also enhance its 
self-assembly in vitro, while for mutant Y231F/Y597F of dynamin-I, such stimulation 
and enhancement were significantly repressed [121].  Src-induced tyrosine-
phosphorylation of dynamin-II, which plays an important role for caveolae-mediated 
endocytosis in endothelial cells, has also been shown to promote its translocation from 
the cytosol to the membrane in vivo [120]. 
 
Study outline 
In this study, our initial observation was that cortactin translocated from the cell 
cortex to the cytoplasmic region of kidney proximal tubule epithelial cells in an ATP-
depletion model of ischemia.  This translocation was reversed after the cells were placed 
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in normal growth medium and allowed to recover.  We then studied the tyrosine 
phosphorylation status of cortactin in both normal growth conditions and ATP-depletion 
conditions.  We found that coincident with ATP-depletion, the tyrosine phosphorylation 
level of cortactin decreased.  Cortactin’s binding to F-actin and the actin nucleator Arp2/3 
complex was also weakened as indicated by co-immunoprecipitation experiments.  In 
addition we propose that cortactin’s direct binding with dynamin-II is important for the 
localization of cortactin and dynamin-II to target membrane locations, such as the 
cytoplasmic membrane regions, or the Golgi membranes, in order to exert their proper 
functions in endocytosis and protein secretion from Golgi.  During ischemia, dynamin-
II’s tyrosine phosphorylation level decreases, the same as cortactin.  Tyrosine-
dephosphorylation of both cortactin and dynamin-II impairs their binding with each other.  
Such decrease of tyrosine-phosphorylation and subsequent dissociation between 
dynamin-II and cortactin down-regulate oligomerization and self-assembly of dynamin-II.  
As a result of these events, dynamin-II’s binding with membrane lipids is disrupted.  
Consequently both dynamin-II and cortactin translocate from membrane locations to 
cytosol, which further contributes to the disruption of endocytosis and protein-secretion 
from Golgi, and consequently to the structural and functional degenerations in kidney 
proximal tubule epithelial cells experiencing ATP-depletion/ischemia.  We studied the 
possible localization of cortactin at trans-Golgi network in kidney proximal tubule 
epithelial cells under both normal growth conditions and ischemic conditions.  We also 
studied the tyrosine-phosphorylation status of dynamin-II before and after ATP-depletion, 
in addition to the possible interaction changes between cortactin and dynamin-II after 
ATP-depletion. 
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2.  Materials and Methods 
 Cell culture. LLC-PK1 porcine proximal tubule cells [American Type Culture 
Collection (ATCC), Manassas, VA] were maintained in 1:1 DMEM/F-12 (SIGMA-
Aldrich Corp.) medium containing 10% fetal bovine serum (FBS), 100IU/ml penicillin, 
100µg/ml streptomycin at 37ºC in a humidified atmosphere of 5% CO2. For ATP-
depletion, cells were incubated in depleted DMEM (medium without amino acids, 
glucose, serum, and antibiotics) and 100nM antimycin A (SIGMA-Aldrich Corp.). If 
recovery of these cells was required, they were rinsed with depleted DMEM and 
incubated in 1:1 DMEM/F-12 (SIGMA-Aldrich Corp.) medium containing 10% FBS, 
100IU/ml penicillin, and 100µg/ml streptomycin.  For Src kinase inhibition, cells were 
incubated for 45 minutes in 1:1 DMEM/F-12 (SIGMA-Aldrich Corp.) medium 
containing 10% FBS, 100IU/ml penicillin, 100µg/ml streptomycin, supplemented with 
50µM Src kinase inhibitor PP2 (10mM solution in DMSO, Calbiochem) (or 0.5% DMSO 
as control of PP2). 
 
Cell lysis and immunoprecipitation. LLC-PK1 cells were grown in 10cm cell culture 
dishes until reaching 100% confluence and then kept for 3 to 4 days. The buffer (50mM 
Tris-HCl pH8.0, 150mM NaCl, 1% Triton-X100, 0.5% Sodium Deoxycholate, 0.1% SDS) 
containing 2mM Na3VO4 and protease inhibitors (1:500 dilution of the protease inhibitors 
cocktail from SIGMA-Aldrich Corp. P8340) was used for cell lysis.  Before cell lysis, the 
LLC-PK1 cells in 10cm dish were washed with ice-cold PBS (supplemented with 1mM 
Na3VO4) for once, and then 1ml ice-cold lysis buffer was added into each dish. After 5 
minutes incubation on ice, the cells were scraped off the dish surface. The lysis buffer 
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containing cells was then incubated at 4ºC on a rotator for 15 minutes, and then 
centrifuged at 16,000 x g for 10 minutes at 4ºC to remove the insoluble fraction. This 
supernatant was used for immunoprecipitation. For cortactin immunoprecipitation, 6µg of 
mouse monoclonal cortactin antibody (clone 4F11, Upstate Biotechnology, Inc.) was 
added to 500µl of cell lysate and incubated on a rotator at 4ºC for 4 hours.  Meanwhile, 
40µl protein A-agarose beads (50% slurry, SIGMA-Aldrich Corp.) were incubated with 
12µg rabbit anti-mouse IgG (Jackson ImmunoResearch) at 4ºC on a rotator for 2 hours. 
After incubation with the cortactin antibody, the cell lysate was added to the protein A-
agarose beads and then incubated on a rotator at 4ºC for 2 hours.  To immunoprecipitate 
dynamin-II, 6µg of rabbit polyclonal dynamin-II antibody (Genetex, Inc.) was added to 
500µl of cell lysate and incubated on a rotator at 4ºC for 4 hours, and then 40µl protein 
A-agarose beads (50% slurry, SIGMA-Aldrich Corp.) were added into the cell lysate and 
incubated on a rotator for 2 hours; after the incubation the protein A-agarose beads were 
washed with the lysis buffer for twice and with PBS for once, and then 50µl SDS sample 
buffer (50mM Tris-HCl pH6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 6M urea, 
2mM EGTA, 0.01% bromophenol blue) was added and heated in a heating block at 80ºC 
for 10 minutes.  The supernatant was then collected for SDS-PAGE. 
 
Antibodies and western blotting. Western blotting was carried out with standard 
procedures.  The primary antibodies included mouse monoclonal cortactin antibody 
(clone 4F11, Upstate Biotechnology, Inc.), rabbit polyclonal cortactin antibody (H-191, 
Santa Cruz Biotechnology), rabbit polyclonal anti-Cortactin (pY421) phospho-specific 
antibody (Biosource), rabbit polyclonal anti-Cortactin (pY466) phospho-specific antibody 
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(SIGMA-Aldrich Corp.), rabbit polyclonal anti-Cortactin (pY486) phospho-specific 
antibody (Chemicon, Australia), biotin-conjugated mouse monoclonal phosphotyrosine 
antibody (4G10, Upstate Biotechnology, Inc.), rabbit polyclonal p34-Arc antibody 
(Upstate Biotechnology, Inc.), mouse monoclonal actin antibody (Chemicon 
International), rabbit polyclonal dynamin-II antibody (Genetex, Inc.).  The secondary 
antibodies included peroxidase-conjugated goat anti-mouse (Jackson ImmunoResearch), 
peroxidase-conjugated donkey anti-rabbit (GE Healthcare). Peroxidase-conjugated 
streptavidin (Upstate Biotechnology, Inc.) was used for the detection of biotin-conjugated 
mouse monoclonal phosphotyrosine antibody (4G10, Upstate Biotechnology, Inc.). 
 
Immunofluorescence microscopy. LLC-PK1 cells were grown on 10x10 mm coverslips 
in 35 mm cell culture dishes until reaching 100% confluence and then kept for 3 to 4 days. 
The cells on coverslips were fixed with 3.7% paraformaldehyde in PBS for 10 minutes at 
room temperature and permeabilized with 0.05% Triton X-100 in PBS for 5 minutes. The 
coverslips were blocked in blocking buffer (PBS containing 10% goat serum and 0.2% 
BSA) at room temperature for 30 minutes. Primary antibody incubation, with 5µg/ml 
mouse monoclonal cortactin antibody (clone 4F11, Upstate Biotechnology, Inc.) and/or 
goat polyclonal TGN38 antibody (Santa Cruz Biotechnology), was done for 1 hour.  After 
brief washing in PBS, the coverslips were then incubated in blocking buffer containing 
fluorescein isothiocyanate-conjugated donkey anti-mouse IgG (1:100 dilution, Jackson 
Immunoresearch) and/or cy5-conjugated donkey anti-goat IgG (1:50 dilution, Jackson 
Immunoresearch), and 0.1 μg/ml rhodamine-phalloidin (Molecular Probes) for 1 hour.  
After brief washing in PBS, the coverslips were mounted with DABCO mounting media 
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(10% 1,4-diazabicyclo-[2,2,2]-octane, 50% glycerol, 2% sodium azide, 1xPBS) on glass 
slides.  The fluorescent images were collected with a Zeiss UV LSM-510 confocal 
microscope system. 
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3.  Results 
ATP-depletion and cortactin localization 
Kidney proximal tubule cells exhibit aggregated F-actin during oxidative stress. 
We examined what actin regulatory proteins might be associated with these structures. In 
LLC-PK1 cells under normal growth conditions, we found relatively stronger localization 
of cortactin at the cell cortex compared with the cytoplasmic regions, using 
immunofluorsence staining (Fig. 4A). F-actin was labeled with rhodamine-conjugated 
phalloidin, and cortactin was labeled with fluorescein isothiocyanate (FITC).  The 
staining of cortactin appeared as small puncta throughout the cytoplasm and it exhibited 
stronger staining patterns at the cell cortex.  Actin staining was in stress fibers (not shown) 
and at the cell cortex.  Cortactin and actin showed colocalization at the cell cortex 
(merged images).  However, after a 90 minute treatment with 100nM antimycin A in 
depleted DMEM to induce ATP-depletion, we found that LLC-PK1 cells exhibited much 
stronger localization of cortactin in the cytoplasmic regions while there was less cortactin 
localized at the cell cortex (Fig. 4B).  Cortactin staining appeared in large aggregates in 
the cytoplasm colocalizing with actin (merged images). Stress fibers were reduced (not 
shown) and actin staining at the cell cortex was increased. After 90 minutes of ATP-
depletion, we returned the LLC-PK1 cells to normal growth conditions. After a 
subsequent 60 minutes of recovery, we found that even though the localization of 
cortactin at the cell cortex was not completely recovered, the large aggregates of cortactin 
and actin had disappeared from the cytoplasmic regions (Fig. 4C). 
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Figure 4. Cortactin localization pattern changes upon ischemia/ATP-depletion in 
LLC-PK1 cells 
 
 
 
 
 
  
 
 
 
             
 
     
A. Control LLC-PK1 cells before ATP-depletion 
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B. LLC-PK1 cells after 90 minutes ATP-depletion 
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C. LLC-PK1 cells after 90 minutes ATP-depletion followed by 60 minutes recovery 
 
Fig. 4. F-actin was labeled with rhodamine-phalloidin (red); cortactin was labeled with 
primary antibody against cortactin and then FITC-conjugated secondary antibody (green).  
In each group of images, the top left one shows only the image from red channel, the top 
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right one shows only the image from green channel, and the bottom left one shows the 
images combined from both red and green channels. 
[A] LLC-PK1 cells under normal growth conditions.  Cortactin exhibited distinct 
localization at the cell cortex and its localization in cytoplasmic regions was at a 
relatively low level. 
[B] LLC-PK1 cells after 90 minutes of ATP-depletion with the treatment of 100nM 
antimycin-A in depleted DMEM.  Compared with cells under normal growth conditions, 
cortactin exhibited much stronger localization at the cytoplasmic regions while there was 
less cortactin localized at the cell cortex in ATP-depleted cells.  F-actin formed 
aggregates in cytoplasmic regions with cortactin colocalization. 
[C] LLC-PK1 cells after 90 minutes of ATP-depletion and then 60 minutes recovery back 
in normal growth conditions.  Although the localization of cortactin at the cell cortex was 
not yet recovered back to the level before ATP-depletion, the aggregates of cortactin and 
actin disappeared from the cytoplasm. 
 
Cortactin was previously reported to localize to Golgi apparatus, and to play an 
important role in post-Golgi transport [52].  Considering the importance of post-Golgi 
protein transport to the establishment and maintenance of cytoplasmic membrane 
dipolarity in kidney proximal tubule cells, we decided to investigate whether cortactin 
also localized to Golgi apparatus in LLC-PK1 cells, and whether this possible 
localization was affected by ATP-depletion.  In immunofluorescence experiments, we 
stained the LLC-PK1 cells with cortactin antibody and an antibody against the trans-
Golgi marker TGN38 either under normal growth conditions or after 90 minutes ATP-
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depletion; however we failed to observe colocalization of cortactin and TGN38 under 
both conditions (Fig. 5). 
 
Figure 5.  No cortactin localization at trans-Golgi was observed in LLC-PK1 cells 
 
 
 
 
 
 
 
 
 
 
 
     
A. LLC-PK1 cells under normal growth conditions 
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B. LLC-PK1 cells under normal growth conditions 
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C. LLC-PK1 cells after 90 minutes ATP-depletion 
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D. LLC-PK1 cells after 90 minutes ATP-depletion 
 
Fig. 5. F-actin was labeled with rhodamine-phalloidin (red); cortactin was labeled with 
primary antibody against cortactin and then FITC-conjugated secondary antibody (green); 
trans-Golgi marker TGN38 was labeled with primary antibody against TGN38 and then 
Cy5-conjugated secondary antibody (blue). 
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[A, B] The same immunofluorescence images of LLC-PK1 cells under normal growth 
conditions.  In B, the rhodamine (red) signal of F-actin was removed and the cy5 (blue) 
signal of TGN38 was shown as green for better viewing purpose. No cortactin 
colocalization with TGN38 at trans-Golgi was observed. 
[C, D] The same immunofluorescence images of LLC-PK1 cells after 90 minutes of ATP-
depletion with the treatment of 100nM antimycin-A in depleted DMEM.  In D, the 
rhodamine (red) signal of F-actin was removed and the cy5 (blue) signal of TGN38 was 
shown as green for better viewing purpose.  No cortactin colocalization with TGN38 at 
trans-Golgi was observed. 
 
The tyrosine phosphorylation level of cortactin decreases in LLC-PK1 cells upon 
ATP-depletion and Src kinase inhibition 
After observing the translocation of cortactin from the cell cortex to the 
cytoplasmic regions in LLC-PK1 cells upon ATP-depletion, we investigated whether 
there was a correlation with its tyrosine phosphorylation level.  LLC-PK1 cells were 
lysed under normal growth conditions or after 90 minutes of ATP-depletion.  Cortactin 
antibody was then used for immunoprecipitation with the lysate. Three tyrosine residues, 
Y421, Y466 and Y482 of cortactin have been identified as the major phosphorylation 
sites of Src kinase. We used phospho-specific antibodies to each one of these three 
tyrosine residues of cortactin to probe the western blot of the cortactin 
immunoprecipitation product.  We found that the tyrosine phosphorylation level of all 
three tyrosine residues (Y421, Y466 and Y482) of cortactin decreased upon ATP-
depletion (top panels of Fig. 6A-C).  In addition, we also treated LLC-PK1 with 50 µM 
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Src kinase inhibitor PP2 under normal growth conditions for 45 minutes.  We found that 
compared with the control LLC-PK1 cells, the cells treated with PP2 also showed 
reduced tyrosine phosphorylation (top panels of Fig. 6A-C). The lower panels (Fig. 6A-C) 
show the quantification of the western blots normalized to their respective control.  The 
cortactin immunoprecipitate was also probed with a non-specific phospho-tyrosine 
antibody (Fig. 6D).  No tyrosine-phosphorylated cortactin was detected after ATP 
depletion or Src kinase inhibition (PP2) treatment. 
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Figure 6. Tyrosine phosphorylation level of cortactin in LLC-PK1 cells decreases 
upon ATP-depletion and Src kinase inhibition 
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A. Phosphorylation of Tyr421 residue of cortactin 
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B. Phosphorylation of Tyr466 residue of cortactin 
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C. Phosphorylation of Tyr482 residue of cortactin 
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D. Tyrosine phosphorylation of cortactin 
 
Fig. 6. After either ATP-depletion or Src kinase inhibition with 50 µM PP2 treatment, 
cortactin was immunoprecipitated from LLC-PK1 cell lysate and then western-blotted 
with specific antibodies against  each of  the three phospho-tyrosine residues, the target 
sites of Src kinase, which are pTyr421 (Fig. 6A), pTyr466 (Fig. 6B), pTyr482 (Fig. 6C), 
and also with the general phospho-tyrosine antibody (Fig. 6D).  For Src kinase inhibition 
with 50 µM PP2 treatment, LLC-PK1 cells were also treated with 0.5% DMSO 
separately as the respective control.  In each single experiment, the phosphorylation level 
of Tyr421, Tyr466 or Tyr482 after ATP-depletion is presented as the percentage compared 
with the sample of normal control, and the phosphorylation level of Tyr421, Tyr466 or 
Tyr482 after PP2 treatment is presented as the percentage compared with the sample after 
DMSO treatment.  The error bars in the columns of normal control and DMSO treatment 
show the standard deviation of the phosphorylation level of Tyr421, Tyr466 or Tyr482 
around the respective average of three experiment repeats. 
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Cortactin’s interaction with F-actin and Arp2/3 complex 
Since we found that the tyrosine phosphorylation level of cortactin decreased 
upon either ATP-depletion or Src kinase inhibition, we decided to investigate whether 
there were also functional changes of cortactin.  Cortactin has many protein targets in 
vivo, and among the interactions with those multiple binding partners, the direct binding 
with F-actin and actin nucleation factor Arp2/3 complex are possibly the most extensively 
studied and also the most critical for cortactin to regulate actin cytoskeleton.  We were 
able to co-immunoprecipitate both actin and Arp2/3 complex with cortactin.  Western-
blotting using the actin (top panel of Fig. 7A) antibody and Arc-p34 (an Arp2/3 complex 
component) (top panel of Fig. 7B) antibody showed decreases in co-immunoprecipitation 
of actin and Arp2/3 complex with cortactin when LLC-PK1 cells were subject to ATP-
depletion or Src kinase inhibition.  These results indicate that tyrosine phosphorylation of 
cortactin is related to its binding with F-actin and actin nucleator Arp2/3 complex.  
Quantifications of the western blots normalized to their respective control are shown in 
Fig. 7A and Fig. 7B in the lower panels. 
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Figure 7. Cortactin’s interactions with F-actin and Arp2/3 complex decrease in 
LLC-PK1 cells upon ATP-depletion and Src kinase inhibition 
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A. Actin co-immunoprecipitation with cortactin 
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B. Arp2/3 complex co-immunoprecipitation with cortactin 
 
Fig. 7. After either ATP-depletion or Src kinase inhibition with 50 µM PP2 treatment, 
cortactin was immunoprecipitated from LLC-PK1 cell lysate and then western-blotted 
with antibody against actin (Fig. 7A) or Arc-p34, a component of Arp2/3 complex (Fig. 
7B).   For Src kinase inhibition with 50 µM PP2 treatment, LLC-PK1 cells were also 
treated with 0.5% DMSO separately as the control.  In each single experiment, the 
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amount of actin or Arp2/3 complex co-immunoprecipitated with cortactin after ATP-
depletion is presented as the percentage compared with the sample of normal control, and 
the amount of actin or Arp2/3 complex co-immunoprecipitated with cortactin after PP2 
treatment is presented as the percentage compared with the sample after DMSO treatment.  
The error bars in the columns of normal control and DMSO treatment show the standard 
deviation of the amount of actin or Arp2/3 complex co-immunoprecipitated with cortactin 
around the respective average of three experiment repeats. 
 
Tyrosine phosphorylation level of dynamin-II decreases in LLC-PK1 cells upon 
ATP-depletion and Src kinase inhibition 
The SH-3 domain at the C-terminus of cortactin binds with proline-rich domain of 
multiple partners in vivo, one of which is dynamin [64].  Dynamin co-localizes with 
cortactin and/or actin structures at multiple cellular locations in vivo [49, 52, 64, 88, 89].  
Like cortactin, dynamin also directly binds with Src kinase [117].  Src-induced tyrosine-
phosphorylation of dynamin-II has been shown to promote its translocation from cytosol 
to membrane in vivo [120].  We investigated if tyrosine phosphorylation level of 
dynamin-II was also affected by ATP-depletion in LLC-PK1 cells.  Using phospho-
tyrosine antibody to western-blot the immunoprecipitated dynamin-II from LLC-PK1 cell 
lysate, we found that the tyrosine-phosphorylation level of dynamin-II decreased after 
either ATP-depletion or Src kinase inhibition with PP2 treatment (Fig. 8A).  Considering 
the importance of both cortactin and dynamin-II to endocytosis and post-Golgi transport 
and their direct in vivo binding, we investigated if their direct binding was affected by 
ATP-depletion and the changes of their tyrosine phosphorylation level.  When we 
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immunoprecipitated cortactin, we were unable to detect dynamin-II in the 
immunoprecipitated protein complex; however when we immunoprecipitated dynamin-II, 
we detected the co-immunoprecipitated cortactin. Contrary to our initial expectations, the 
western-blotting results did not show major changes of cortactin co-immunoprecipitation 
with dynamin-II after either ATP-depletion or Src kinase inhibition with PP2 treatment 
(Fig. 8B).  The data suggests that there is no major change of cortactin and dynamin-II 
interaction in vivo in LLC-PK1 cells after those treatments. 
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Figure 8. ATP-depletion or Src kinase inhibition leads to the decrease of the 
dynamin-II tyrosine phosphorylation level but does not affect the interaction 
between cortactin and dynamin-II 
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A. Tyrosine phosphorylation of dynamin-II 
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B. Cortactin co-immunoprecipitation with dynamin-II  
 
Fig. 8. After either ATP-depletion or Src kinase inhibition with 50 µM PP2 treatment, 
dynamin-II was immunoprecipitated from LLC-PK1 cell lysate and then western-blotted 
with biotin-conjugated phospho-tyrosine antibody (Fig. 8A) or cortactin antibody (Fig. 
8B).   For Src kinase inhibition with 50 µM PP2 treatment, LLC-PK1 cells were also 
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treated with 0.5% DMSO separately as the control.  In each single experiment, the 
tyrosine phosphorylation level of dynamin-II after ATP-depletion is presented as the 
percentage compared with the sample of normal control, and the tyrosine phosphorylation 
level of dynamin-II after PP2 treatment is presented as the percentage compared with the 
sample after DMSO treatment.  The error bars in the columns of normal control and 
DMSO treatment show the standard deviation of the tyrosine phosphorylation level of 
dynamin-II around the respective average of three experiment repeats.  In each single 
experiment, the amount of cortactin co-immunoprecipitated with dynamin-II after ATP-
depletion is presented as the percentage compared with the sample of normal control, and 
the amount of cortactin co-immunoprecipitated with dynamin-II after PP2 treatment is 
presented as the percentage compared with the sample after DMSO treatment.  The error 
bars in the columns of normal control and DMSO treatment show the standard deviation 
of the amount of cortactin co-immunoprecipitated with dynamin-II around the respective 
average of five experiment repeats. 
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4.  Discussion 
The epithelial cells lining the proximal tubule of the nephron are particularly 
susceptible to ischemic renal injury.  The disruption of the actin cytoskeleton in proximal 
tubules begins at a very early stage of ARI. The actin cytoskeleton is also responsible for 
the establishment and maintenance of epithelial cell polarity. Therefore, the study of actin 
cytoskeleton regulators, in particular the changes of their function during renal ischemia, 
is vital to the understanding of the pathological etiology of ARI.  In this study, we used an 
in vitro cell culture system to model ischemia by incubation with antimycin A in a 
substrate depleted medium, resulting in ATP depletion.  We observed actin aggregates in 
LLC-PK1 cells upon ATP-depletion.  We also found that with ATP depletion cortactin 
translocated from the cell cortex to the cytoplasmic regions and colocalized in actin 
aggregates.  Cytoplasmic actin aggregates resulting from ATP depletion were first 
reported by Hinshaw et al. [122].  More recently, F-actin aggregates were found to form 
merely by disrupting F-actin filament dynamics with jasplakinolide, and cortactin was 
found in these aggregates [79].  It has been suggested that the formation of actin 
aggregates during ATP depletion is beneficial to the cell; for example the actin turnover 
uses up to 50% of the ATP in neurons while the actin aggregates formed in neurons 
during ATP stress are less dynamic and consume much less ATP [123].  In kidney 
ischemia, conservation of ATP by  actin aggregate formation may allow the epithelium to 
cope with low oxygen tension for longer than it would otherwise.  After LLC-PK1 cells 
were returned to normal growth conditions for one hour, cortactin/actin aggregates 
disappeared. 
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Post-translational modification of proteins by kinase phosphorylation is an 
important regulatory mechanism.  Protein phosphorylation generally decreases 
significantly during ischemia [124].  However, not all proteins become dephosphorylated.  
For example, AMPK (AMP-activated protein kinase) becomes phosphorylated during 
ischemia [125].  With this in mind, we decided to test whether the tyrosine 
phosphorylation of cortactin changed during ATP depletion.  The immunoprecipitation 
and western blotting results showed that the tyrosine phosphorylation level of cortactin 
decreased during ATP-depletion.  In addition the phosphorylation level of cortactin on 
Y421, Y466 and Y482 residues also appeared to decrease when the cells were subject to 
Src kinase inhibition.  Although the decrease of Y466 and Y482 phosphorylation after Src 
kinase inhibition was not statistically significant (as shown by the one-sided p value in t-
test), that could be due to the small number of experiment repeats.  Meanwhile, when we 
probed the cortactin immunoprecipitate with the general phospho-tyrosine antibody in 
western-blotting analysis, there was no tyrosine-phosphorylated cortactin detected after 
either ATP-depletion or Src kinase inhibition, which proved that the overall tyrosine 
phosphorylation of cortactin decreased upon ATP-depletion or Src kinase inhibition. 
We were also interested in finding out whether cortactin’s interaction with its 
targets of regulation changed in parallel with the decrease of its tyrosine phosphorylation 
level.  To investigate these interactions, we immunoprecipitated cortactin from normal 
control and ATP depleted cells and probed for Arc-p34, a protein component of the 
Arp2/3 complex, as well as for actin.  In both cases there appeared to be a decrease in 
terms of their interactions with cortactin in ATP-depleted LLC-PK1 cells and cells treated 
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with Src kinase inhibitor.  Once again the small number of experiment repeats might have 
contributed to the fact that some of the results were not statistically significant. 
Many studies have been published on how tyrosine phosphorylation affects 
cortactin’s cellular function.  One major conclusion is that tyrosine phosphorylation 
regulates cortactin’s targeting to the cell cortex [74, 84, 85].  Our study shows that this 
relationship also exists in kidney epithelial cells.  Meanwhile, during ATP depletion the 
decrease of cortactin tyrosine phosphorylation also happens in parallel with the 
redistribution of cortactin from the cortex to cytoplasmic aggregates containing actin.  
Our previous study shows in LLC-PK1 cells, the F-actin content increases while G-actin 
monomer content decrease after ATP-depletion, in comparison with normal growth 
conditions [36].  Previously it was reported that in CHO cells F-actin depolymerization 
induced by LB (latrunculin-B) led to Fyn/Fer kinase-mediated tyrosine phosphorylation 
of cortactin at the same target sites as Src kinase, and in LB-treated cells tyrosine-
phosphorylated cortactin predominantly distributed in cytoplasmic regions; on the other 
hand the F-actin polymerization induced by jasplakinolide and the concomitant actin-
cortactin clustering reduce cortactin tyrosine phosphorylation [69].  In our study we 
observed an increase of F-actin content in cytoplasmic regions in LLC-PK1 cells after 
ATP-depletion and also observed cortactin translocating from cell cortical region to 
cytoplasmic regions and colocalizing with the F-actin aggregates at cytoplasmic regions; 
therefore it is possible that such an increase of F-actin content in cytoplasmic regions of 
LLC-PK1 cells after ATP-depletion inhibits the tyrosine phosphorylation of cortactin by 
Fyn/Fer kinases, which further contributes to the overall decrease of cortactin tyrosine 
phosphorylation. 
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The cortical actin cytoskeleton plays a critical role in establishing and maintaining 
the apical and basolateral membrane polarity, and its disruption to a significant extent 
precedes the membrane changes during ischemia.  Ischemic injury also disrupts the 
localization of apical and basolateral membrane components.  The correct targeting of 
protein components of the apical and basolateral membranes to surface membrane 
destinations after synthesis at the ER, modification at and transportation from Golgi; as 
well as their recycling from the surface membrane in clathrin-coated vesicles by 
endocytosis and then recycling back to the original surface membrane domains, or 
transcytosis to particular surface membrane domains for enrichment; all these processes 
are very important for establishing and maintaining apical and basolateral membrane 
polarity, and also important for the proper filtration function of the proximal tubule; 
therefore they could be disrupted by ischemia [13, 39, 40].  Cortactin, along with its 
direct binding partner dynamin, have been reported to be important for receptor-mediated 
endocytosis and post-Golgi transport [49-52].  We speculated that during ischemia/ATP-
depletion in kidney epithelial cells, the changes of cortactin’s tyrosine phosphorylation 
level and its localization pattern also affected its normal function in endocytosis and post-
Golgi transports.  However by immunofluorescence microscopy, we failed to detect the 
colocalization of cortactin with trans-Golgi protein TGN38 in both normal control and 
ATP-depleted LLC-PK1 cells, even though such a colocalization was previously reported 
in different types of cells [52].  Recently it was reported that receptor-mediated 
endocytosis involved tyrosine phosphorylation of cortactin, and src-mediated 
phosphorylation of cortactin enhanced its association with dynamin-II as shown by in 
vitro study [83].  We detected endogenous cortactin in the protein complexes from 
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dynamin-II immunoprecipitation with LLC-PK1 cell lysate, but the western-blotting 
results did not show any major change of interaction between cortactin and dynamin-II 
when the LLC-PK1 cells were subject to ATP-depletion or Src kinase inhibition.  
Therefore, whether in kidney epithelial cells the ATP-depletion disrupts cortactin’s 
normal function in post-Golgi transports and endocytosis through the decrease of its 
tyrosine phosphorylation level, and whether these functional disruptions of cortactin 
further contribute to the ischemic cellular injury, these questions remain to be answered 
by further investigations. 
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5.  Summary 
Cortactin, an important regulator of actin assembly and organization, plays an 
important role in endocytosis and post-Golgi transport.  One mechanism controlling 
cortactin’s cellular activity and localization is the phosphorylation of several tyrosine 
residues located within the proline-rich domain of cortactin by different kinases including 
Src.  Using LLC-PK1 cells (a porcine kidney proximal tubule epithelial cell line) as a cell 
culture model of renal ischemia, we found that cortactin translocated from the cell cortex 
to the cytoplasmic regions upon ATP-depletion.  Even though cortactin was previously 
reported to localize on trans-Golgi network, we were unable to detect the colocalization 
of cortactin and the trans-Golgi marker TGN38 in LLC-PK1 cells under either normal 
growth conditions or ATP-depletion.  Meanwhile the overall tyrosine phosphorylation 
level of cortactin as well as on each of the three target sites (Y421/466/482) of Src family 
kinases decreases in LLC-PK1 cells upon ATP-depletion or inhibition of Src kinase 
activity.  In addition, co-immunoprecipitation assays indicate that cortactin’s in vivo 
interaction with F-actin and the actin nucleator Arp2/3 complex is also weakened upon 
ATP-depletion or inhibition of Src kinase activity.  Dynamin-II, a GTPase with a critical 
role in multiple cellular functions including endocytosis, vesicle traffic in and out of the 
Golgi, directly binds with cortactin and is also a regulator of dynamic actin cytoskeleton 
structures.  We found that the overall tyrosine phosphorylation level of dynamin-II 
decreased in LLC-PK1 cells upon ATP-depletion or inhibition of Src kinase activity.  
Previously it was reported that src-mediated phosphorylation of cortactin enhanced its 
association with dynamin-II, but in our study the co-immunoprecipitation assays did not 
show any major change of interaction between cortactin and dynamin-II interaction when 
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LLC-PK1 cells were subject to ATP-depletion or Src kinase inhibition.  These results 
suggest that tyrosine phosphorylation plays an important role in regulating cortactin’s 
cellular function and localization in the scenario of kidney ischemia.  Further studies 
could be done on how cortactin’s tyrosine phosphorylation affects its interactions with 
proteins other than dynamin-II, and how these interactions subsequently affects actin 
cytoskeleton and the apical/basolateral membrane dipolarity in kidney proximal tubule 
epithelia.  These studies will significantly assist us with better understanding of the 
mechanisms by which the actin cytoskeleton dysregulation, a critical feature of cellular 
injury caused by kidney ischemia, occurs. 
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CHAPTER III 
 
AMP-Activated Protein Kinase is an Upstream Regulator of Rho GTPases Activity 
and Cytoskeletal Organization during ATP-Depletion in a Cell Culture Model of 
Ischemic Renal Injury 
 
1.  Introduction 
Rho GTPases and renal ischemia 
The Rho family of small GTPases in eukaryotic cells, encompassing more than 20 
members of intracellular signaling molecules, directly interact with numerous proteins 
and are involved in the regulation of multiple cellular functions and processes including 
cell cycle control, cell morphogenesis, cell migration, apoptosis and so on [126].  In 
terms of biochemical functions, the Rho family GTPases regulate enzymatic activities, 
affect gene expression, in addition to controlling the actin and microtubule cytoskeleton, 
which has been the most extensively studied so far.  Other than several “atypical” 
members which are predominantly GTP-bound, the majority of Rho GTPases switch 
between the GTP-bound active state and the GDP-bound inactive state.  When bound to 
GTP, Rho GTPases interact and activate downstream effectors to regulate multiple 
cellular processes.  Regulated by upstream signaling pathways, a large family of GTPase-
activating proteins (GAP) significantly stimulate the GTPase activity of Rho proteins 
(which is usually low) to catalyze the hydrolysis of GTP into GDP.  By promoting the 
release of GDP from and the binding of GTP to Rho proteins, another large number of 
guanine nucleotide-exchange factors (GEFs) activate them.  A relatively small number of 
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Figure 9. Rho GTPase functional cycle 
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Fig. 9. The majority of Rho family GTPases cycle between the inactive GDP-bound form 
and the active GTP-bound form (see text for details). 
 
guanine nucleotide-dissociation inhibitors (GDIs) bind to C-terminal prenyl groups on 
some GDP-bound Rho proteins, thereby sequestering them in the cytoplasm away from 
the upstream regulators and downstream targets [127] (Fig. 9).  Among all the Rho family 
GTPases, Rho, Rac and Cdc42 are so far the best-understood ones.  In terms of regulating 
the actin cytoskeleton, it is commonly agreed that the activation of Rho, Rac and Cdc42 
regulates the assembly of actin-myosin filaments (stress fibers) and associated cell-
substrate focal adhesion complexes, the actin filament meshwork at the cell periphery to 
produce protrusive lamellipodia and membrane ruffles, and the highly dynamic 
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finger-like actin-rich protrusions known as filopodia which are important for cells to 
sense the environment, respectively. 
The apical and basal membrane dipolarity is critical for the normal function of 
epithelial cells.  The homophilic interactions among E-cadherin, which produce stable 
cell-cell adherens junctions through the further recruitment of intracellular proteins and 
the actin cytoskeleton, are necessary for the establishment of cell polarity.  Rho, Rac and 
Cdc42 are all implicated in adherens junction assembly.  In addition the claudin-mediated 
tight junctions assembled apically to adherens junctions are also needed for cell polarity 
establishment, and for this process Cdc42 is considered to be a regulator [126].  Rho and 
Rac are involved in signaling from the extracellular environment for the establishment of 
epithelial cell polarity, and finally Cdc42 is required for vesicle trafficking to reinforce 
membrane polarity [128].  In previous research conducted in our lab, we found that in 
kidney epithelial cells the activity of Rac and RhoA but not Cdc42 significantly and also 
very quickly decreased with ATP-depletion [129].  On the other hand certain aspects of 
the cytoskeleton disruptions exhibited in the cell culture model of kidney ischemia can be 
reversed by manipulating RhoA activity [130-132].  Our research has established that 
Rho GTPases signaling is very important to the process through which the energy and 
ATP level decrease leads to actin cytoskeleton dysregulation during kidney ischemia, and 
the next step of our study will be to elucidate how the GTPase signaling is affected 
during ATP-depletion.  We propose that the AMP-activated protein kinase (AMPK), 
whose regulation and activity acts as an ultrasensitive system for monitoring cellular 
energy change in all eukaryotic cells, which was also found to be important for the 
maintenance of epithelial cell polarity [133-135], works upstream of Rho GTPases 
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signaling when Rho GTPase activity changes quickly as a response to the decrease of 
energy and ATP level upon kidney ischemia. 
 
AMP-activated protein kinase 
AMPK was initially identified as a mammalian protein kinase that phosphorylates 
and inactivates enzymes of lipid synthesis, for example acetyl-CoA carboxylase, and this 
is still considered to be one of the major cellular functions of AMPK [136].  Mammalian 
AMPK is highly sensitive to the cellular AMP/ATP ratio and is primarily activated by 
metabolic stresses that either disrupt the synthesis of ATP or stimulate the consumption of 
ATP. 
 
Figure 10. The regulation of AMPK by energy level 
AMPK Kinase
 
Fig. 10. The Thr172 phosphorylation and kinase activity of AMPK are regulated by ATP 
and AMP levels   (see text for details). 
 
AMPK exists as a hetero-trimeric complex composed of catalytic α subunit and 
scaffolding β subunit and regulatory γ subunit.  The binding of AMP to the γ subunit 
stimulates the kinase activity of the α subunit, and also promotes the phosphorylation of 
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Thr172 residue in the kinase domain of the α subunit by upstream kinases, such as tumor 
suppressor LKB1 and calmodulin-dependent protein kinase kinase β.  The 
phosphorylation of Thr172 residue is essential for the kinase activity of AMPK, and also 
is frequently studied as an indicator of AMPK activity [137].  Meanwhile AMP inhibits 
the dephosphorylation of Thr172 in the α subunit, and this effect of AMP is antagonized 
by high concentration of ATP [138, 139] (Fig. 10).  That is the mechanism by which 
AMPK works as an energy sensor. 
Since the discovery of AMPK, it has been extensively studied in terms of its 
regulation of glucose uptake, gene transcription, cell growth and proliferation, and most 
recently its regulation of the establishment and maintenance of cell polarity.  For the 
regulation of cell growth and proliferation, one of the downstream targets of AMPK is 
mammalian target of rapamycin (mTOR) complex (Fig. 11), a critical integrator of both 
intracellular and extracellular signals leading to cell growth and survival [140].  AMPK 
directly phosphorylates TSC2 (tuberous sclerosis complex) protein which forms a 
heterodimer protein complex with TSC1 in vivo [141].  The phosphorylation of TSC2 by 
AMPK stimulates its GAP (GTPase activating protein) function on downstream effectors, 
one of which is Rheb protein [142].  Rheb has a low basal level of GTPase activity and 
has been identified as a regulator of the mTOR complex 1.  Both GDP-bound and GTP-
bound Rheb bind directly with mTOR complex 1, but only the GTP-bound Rheb 
stimulates mTOR complex 1 activity [143].  AMPK was recently found to phosphorylate 
directly one of the components of mTOR complex 1, Raptor, on two well-conserved 
serine residues, and this phosphorylation is required for the inhibition of mTOR complex 
1 induced by energy stress [144]. 
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Figure 11. From AMPK activation to actin cytoskeleton dysregulation 
 
Fig. 11. We propose that AMPK acts as a sensor of energy and ATP level decrease in 
kidney ischemia and depresses the activity of signaling pathways through TSC1/2, Rheb 
GTPase and mTOR kinase in mTOR complexes, leading to disrupted Rho GTPase 
activity and eventually cytoskeletal dysregulation   (see text for details). 
 
mTOR complex 
The TOR1 and TOR2 genes were initially identified in the study of yeast cell 
cycle arrest caused by immunosuppressive drug rapamycin [145, 146].  Subsequently the 
TOR genes were also discovered in higher eukaryotes, including mammals.  Since then 
mTOR has been extensively studied because of its essential role in cell growth and its 
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involvement in human tumorigenesis.  The mTOR kinase is an atypical serine/threonine 
protein kinase with a predicated molecular weight of 290 kDa, and in vivo it exists within 
even bigger protein complexes.  Two major protein complexes containing mTOR, which 
are termed mTOR complex 1 and mTOR complex 2, have been identified so far [147].  
The mTOR complex 1 has been identified as an important regulator of protein synthesis.  
The active mTOR complex 1 binds to the eIF3 (eukaryotic initiation factor 3) and 
phosphorylates the S6K1 and 4EBP1 that are bound to eIF3 under basal conditions.  The 
phosphorylation of S6K1 and 4EBP1 eventually leads to the stimulation of protein 
translation [148].  The mTOR complex 1 is composed of mTOR, Raptor and mLST8, and 
is sensitive to rapamycin inhibition.  So far, four components, mTOR, Rictor, Sin1 and 
mLST8 have been identified in mTOR complex 2, which is generally considered to be 
insensitive to rapamycin, although there is data suggesting that prolonged rapamycin 
treatment inhibits the assembly of mTOR complex 2 and also affects its downstream 
signaling [149].  Unlike mTOR complex 1, the major cellular function of mTOR complex 
2 has been identified as the control of actin cytoskeleton and it is suggested to work at the 
upstream of Rho GTPases [150, 151].  In our previous research, we also found that when 
either mTOR or Rictor protein expression was knocked down with siRNA in renal 
epithelial cells, the RhoA activity decreased in parallel. 
Although the study of mTOR complex 1 had been historically focused on its 
regulation of cell growth and proliferation, recent research showed that it was also 
involved in the regulation of actin cytoskeleton.  In different types of human tumor cells, 
rapamycin treatment was found to inhibit type I insulin growth factor-stimulated cell 
motility by preventing F-actin reorganization and inhibiting the phosphorylation of focal 
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adhesion proteins.  The inhibitory effect of cell motility by rapamycin was found to be 
mediated through the inhibition of the kinase activity of mTOR complex 1.  Meanwhile 
the disruption of either mTOR complex 1 or mTOR complex 2 by knocking down protein 
expression of either Raptor or Rictor with shRNA inhibited cell motility [152,153]. 
 
Study outline 
Previously AMPK was found to be activated in vivo by acute renal ischemia in 
animal model (induced by cross-clamping the renal pedicle in the rat) [154].  In our study 
we also found that AMPK was activated after 30 minutes ATP-depletion in an in vitro 
model of ischemic injury in cultured renal epithelial cells (mouse S3 cell line).  Our 
unpublished study showed that ATP-depletion decreased the phosphorylation of mTOR at 
the Ser2448 (which is considered to be the indicator of overall mTOR kinase activity 
level [155]).  Therefore we propose that AMPK acts as a sensor of energy and ATP level 
decrease in kidney ischemia and depresses the activity of signaling pathways through 
TSC1/2, Rheb GTPase and mTOR kinase in mTOR complex, leading to disrupted Rho 
GTPase activity and eventually cytoskeletal dysregulation. 
To test this hypothesis we used S3 epithelial cells derived from the proximal 
tubule in mouse kidney in a cell culture model of renal ischemia using antimycin A and 
substrate depletion to induce ATP depletion.  In this study we used the phosphorylation of 
Thr172 of the AMPK α-subunit as a measure of AMPK activation, and also utilized pull-
down assays of GTP-bound RhoA and Rac1 to measure the GTPase activity of RhoA and 
Rac1 proteins.  We found that AMPK was rapidly activated (≤5 minutes) by ATP 
depletion from the low basal activity level in normal control S3 cells, and there was a 
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corresponding decrease in RhoA and Rac1 activity.  We used graded concentrations of 
glucose in substrate-depleted growth medium containing antimycin A to achieve 
intermediate levels of ATP depletion, confirmed by HPLC analysis.  We found 
intermediate levels of AMPK activity at these intermediate ATP levels.  We also found 
that the GTPase activity of RhoA and Rac1 correlated inversely with the activity of 
AMPK.  AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) and the anti-diabetic 
drug metformin are two cell-permeable reagents that have been found to activate AMPK 
and are widely used in studies of AMPK [156-158].  We found that the activation of 
AMPK using AICAR or metformin suppressed RhoA (but not Rac1) activity, consistent 
with our hypothesis; meanwhile after either metformin or AICAR treatment the stress 
fibers of S3 cells exhibited morphological changes.  Compound C, a cell-permeable small 
molecule chemical, is a selective, ATP-competitive inhibitor of AMPK [158, 159].  We 
found that treating S3 cells with compound C continuously before and during ATP-
depletion partially inhibited the activation of AMPK caused by ATP-depletion, and also 
partially rescued the disruptions of stress fibers caused by ATP-depletion.  But we did not 
detect a significant change of RhoA and Rac1 activity when AMPK activation during 
ATP-depletion was partially inhibited by compound C.  Therefore our data support the 
hypothesis that the activation of AMPK is at the upstream of the signaling pathways 
downregulating RhoA activity during ATP depletion that eventually leads to actin 
cytoskeletal disruption. 
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2.  Materials and Methods 
Cell culture and ATP-depletion. The S3 cells were originally derived from a transgenic 
mouse carrying the large T antigen of the SV40 virus. They were initially isolated by 
microdissection of the S3 segment of the proximal tubule from this mouse.  We chose this 
cell line instead of the LLC-PK cells due to the better availability of murine reagents and 
also because the proximal tubule S3 segment is particularly susceptible to ischemic injury 
and cytoskeletal disruption.  The S3 cells were maintained in S1 medium containing 7% 
fetal bovine serum (FBS), 100IU/ml penicillin, 100µg/ml streptomycin at 37ºC in a 
humidified atmosphere of 38% O2 and 5% CO2.  For ATP-depletion, cells were incubated 
in depleted DMEM (medium without amino acids, glucose, serum, and antibiotics) with 
100nM antimycin A (SIGMA-Aldrich Corp.) for 30 minutes.  For graded ATP-depletion, 
the depleted DMEM was supplemented with both 100nM antimycin A and different 
concentrations of glucose (500mg/L, 1000mg/L, 1500mg/L and 2000mg/L respectively). 
 
AMPK activation and inhibition.  For AMPK activation with either AICAR (EMD 
Chemicals Inc.) or metformin (SIGMA-Aldrich Corp.), S3 cells were treated with regular 
growth medium supplemented with either 2mM AICAR for 90 minutes or 10mM 
metformin for 4 hours before cell lysis or fixation with 3.7% paraformaldehyde.  For 
AMPK inhibition with compound C (EMD Chemicals Inc.), S3 cells were treated with 
regular growth medium supplemented with 100µM compound C for 4 hours before 30 
minutes ATP-depletion, and the medium during ATP-depletion was also supplemented 
with 100µM compound C.  For control purpose, the compound C was replaced with 1% 
DMSO and all the other conditions were the same. 
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Cell lysis and Rho GTPases pull-down assay. S3 cells were grown in 35mm cell culture 
dishes until reaching 100% confluence and then kept for 3 to 4 days with daily feeding of 
fresh growth medium. The lysis buffer (25mM Tris-HCl pH7.5, 150mM potassium 
acetate, 5mM EDTA, 5mM EGTA, 10mM DL-Dithiothreitol, 10% glycerol, 1% Triton-
X100, 60mM Octyl-β-D-Glucopyranoside) supplemented with 10mM NaF, protease 
inhibitors (1:200 dilution of the protease inhibitor cocktail from SIGMA-Aldrich Corp. 
P8340) and phosphatase inhibitors (1:100 dilution of the phosphatase inhibitor cocktail 1 
from SIGMA-Aldrich Corp. P2850), was used for cell lysis.  Before cell lysis, the S3 
cells in 35mm dish were washed with ice-cold PBS for once, and then 150µl ice-cold 
lysis buffer was added into each dish.  After 10 minutes incubation on ice, the cells were 
scraped off the dish surface. The lysis buffer containing cells was then centrifuged at 
10,000 x g for 1 minute at 4ºC to remove the insoluble fractions. The supernatant was the 
cell lysate used for total proteins precipitation or Rho GTPases pull-down assay.   
Acetone was used for the total proteins precipitation from the cell lysate of S3 cells.  For 
Rho GTPases pull-down assay, 20µl cell lysate (for RhoA pull-down) or 35µl cell lysate 
(for Rac1 pull-down) was added into 30µl glutathione-agarose beads that were either pre-
bound with recombinant GST fusion protein containing the RhoA binding domain of Rho 
kinase (which only binds the GTP-bound form of RhoA), or pre-bound with recombinant 
GST fusion protein containing the CRIB (GTPase binding-domain) of PAK kinase 
(which binds the GTP-bound form of Rac and Cdc42).  After 1 hour incubation on a 
rotator at 4ºC, the beads were then washed for three times with washing buffer (25mM 
Tris-HCl pH7.5, 150mM potassium acetate, 5mM EDTA, 5mM EGTA, 10mM DL-
Dithiothreitol, 10% glycerol).  After the washing, 50µl SDS sample buffer (50mM Tris-
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HCl pH6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 6M urea, 2mM EGTA, and 
0.01% bromophenol blue) was added into the beads and then the beads were heated on a 
heating block at 80ºC for 10 minutes.  The supernatant was then collected for SDS-PAGE. 
 
Antibodies and western blotting.  Western blotting was carried out with standard 
procedures.  The primary antibodies included rabbit monoclonal phospho-AMPKα 
(pThr172) antibody (Cell Signaling Technology, #2535), rabbit polyclonal AMPKα 
antibody (Cell Signaling Technology, #2532), rabbit polyclonal RhoA antibody (Santa 
Cruz Biotechnology, Inc., SC-179), mouse monoclonal RhoA antibody (Santa Cruz 
Biotechnology, Inc., SC-418), and mouse monoclonal Rac1 antibody (Millipore Corp., 
clone 23A8).  The secondary antibodies included peroxidase-conjugated sheep anti-
mouse (GE Healthcare), peroxidase-conjugated donkey anti-rabbit (GE Healthcare). 
 
Expression of GST-fusion proteins for Rho GTPases pulldown assay.  LB plates 
containing carbenicillin were streaked with the glycerol stock of E-coli cells expressing 
the GST-fusion proteins.  A single colony was picked from the LB plate and was 
inoculated into each of the 4 flasks of 100ml LB medium containing carbenicillin for 
overnight growth on shaker at 37ºC and 250 rpm.  The overnight cultures were 
transferred into 4 flasks of 1 litre LB medium for 2 hours growth on shaker at 37ºC and 
250 rpm, and then the GST-fusion proteins expression was induced with 1mM IPTG for 3 
hours.  The cells were collected by centrifugation at 5,000 x g for 15 minutes at 4ºC.  The 
cell pellets were resuspended with buffer A (50mM Tris-HCl pH7.5, 50mM potassium 
acetate, 5mM MgSO4, 10mM DL-Dithiothreitol, 10% glycerol, 50µM BHT) that was 
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supplemented with protease inhibitors (1:100 dilution of the protease inhibitor cocktail 
from SIGMA-Aldrich Corp. P8340).  The cells were lysed with a French press for twice 
and then centrifuged for 10 minutes at 10,000 x g and 4ºC.  The supernatant was 
collected and added into 2ml of glutathione agarose beads (50% slurry, SIGMA-Aldrich 
Corp.) that was pre-washed with buffer A once.  The beads were incubated at 4ºC for 1 
hour on a rotator and then washed with buffer B (same recipe as buffer A except 150mM 
potassium acetate) for twice followed by washing with buffer C (same recipe as buffer A 
except 500mM potassium acetate) for twice.  The beads were then washed with buffer D 
(25mM Tris-HCl pH7.5, 1mM MgSO4, 1mM DL-Dithiothreitol, 10% glycerol, 50µM 
BHT) for twice and kept in buffer D as 50% slurry.  The beads were aliquoted and stored 
in liquid nitrogen for future Rho GTPases pull-down assays. 
 
F-actin labeling and microscopy.  S3 cells were grown on 10x10mm coverslips in 35 
mm cell culture dishes until 80-90% confluence. The cells on coverslips were fixed with 
3.7% paraformaldehyde in PBS for 10 minutes at room temperature and then 
permeabilized with 0.05% Triton X-100 in PBS for 5 minutes. The coverslips were 
blocked in blocking buffer (PBS containing 10% goat serum and 0.2% BSA) at room 
temperature for 30 minutes and then incubated in the same blocking buffer supplemented 
with 0.1μg/ml rhodamine-phalloidin (Molecular Probes) for 1 hour to label the F-actin.  
After brief washing in PBS, the coverslips were mounted with DABCO mounting media 
(10% 1,4-diazabicyclo-[2,2,2]-octane, 50% glycerol, 2% sodium azide, 1x PBS) on glass 
slides.  The fluorescent images were collected with a Zeiss UV LSM-510 confocal 
microscope system. 
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3.  Results 
ATP-depletion rapidly activates AMPK 
In our previous study, we found that AMPK was activated after 30 minutes of 
ATP-depletion in S3 cells as indicated by the significant increase of Thr172 
phosphorylation level of AMPK α subunit from the very low basal level under normal 
growth conditions.  Since we knew that the activity of RhoA and Rac1 decreased very 
rapidly with ATP-depletion, we investigated whether AMPK was also activated by ATP-
deletion rapidly.  We ATP-depleted S3 cells in a time course from 5 up to 90 minutes.  We 
found that after only 5 minutes ATP-depletion, the phosphorylation of Thr172 already 
reached the highest level and then stayed at the plateau during the entire time course, 
which indicated that AMPK was strongly activated within only 5 minutes ATP-depletion.  
The result of a typical experiment is shown in Fig. 12. 
 
RhoA and Rac1 activity correlates inversely with the activity of AMPK at different 
levels of ATP-depletion 
Since ATP-depletion was achieved by nutrient depletion in growth media 
combined with antimycin A treatment, we wanted to determine whether it was the energy 
and ATP level decrease in S3 cells that activated AMPK or it was the drug effect of 
antimycin A instead.   To achieve that purpose, we added different amounts of glucose 
into the media (0mg/L to 2,000mg/L) during ATP-depletion.  The intermediate levels of 
ATP-depletion were confirmed by HPLC measurements of nucleotide concentrations in 
the acetonitrile extracts of S3 cells.  With the increase of glucose concentrations, the ATP 
and GTP levels increased (only ATP results are shown here) while the AMP level and 
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Figure  12. AMPK activity during time course of ATP-depletion 
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Fig. 12. AMPK was rapidly activated by ATP-depletion (≤ 5 minutes).  The activity of 
AMPK in S3 cells was measured with the antibody against the phospho-Thr172 of 
AMPK α subunit, and normalized against the total AMPK. 
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AMP/ATP ratio decreased (Fig. 13).  At these intermediate levels of ATP-depletion, 
AMPK exhibited intermediate levels of activity as indicated by the intermediate 
phosphorylation levels of Thr172 of the AMPK α subunit (Fig. 14).  We also measured 
the RhoA and Rac1 activity separately at these intermediate levels of ATP-depletion as 
well as under the regular ATP-depletion and normal growth conditions by the widely-
employed method of “pulling-down” the fraction of RhoA or Rac1 protein that was in the 
active, GTP-bound state from the lysate of S3 cells.  After normalizing the amount of 
GTP-bound RhoA/Rac1 protein to the total RhoA/Rac1 protein in the lysate of S3 cells, 
we were able to compare the activity of RhoA/Rac1 under different conditions.  We 
found that at the intermediate levels of ATP-depletion, RhoA and Rac1 also exhibited 
intermediate levels of GTPase activity, which was higher than after ATP-depletion 
without glucose supplementation, and lower than under normal growth conditions (Fig. 
15A-B).  These results show that the AMPK activity is inversely co-related with the 
energy and ATP level in S3 cells during ATP-depletion, and also inversely co-related with 
the GTPase activity of RhoA and Rac1.  The results also indicate that AMPK activity and 
RhoA/Rac1 activation are not affected by antimycin A treatment per se, but rather by 
cellular ATP levels. 
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Figure 13. Nucleotide concentrations in S3 cells upon graded ATP-depletion 
 
 
 
 
 
 
 
Fig. 13. Graded ATP-depletion was achieved by adding graded concentrations of glucose 
into the nutrient-depleted growth media containing 100nM antimycin A.  Nucleotide 
concentrations were measured by HPLC in the acetonitrile extracts of S3 cells. 
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Figure 14. AMPK activity upon graded ATP-depletion 
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Fig. 14. AMPK exhibited intermediate levels of activity at intermediate ATP levels upon 
graded ATP-depletion.  The activity of AMPK in S3 cells lysate was measured with the 
specific antibody against the phospho-Thr172 of AMPK α subunit, and normalized 
against the total AMPK.  ATP depletion was done for 30 minutes.  In each single 
experiment, the activity of AMPK in all the other samples are presented as percentages 
compared with the sample of regular ATP-depletion with 0mg/L glucose.  The error bar in 
the column of ATP-depletion with 0mg/L glucose shows the standard deviation of AMPK 
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activity around the average of 5 experiment repeats.  The underlines (A, B, and C) are 
used to group samples.  The data values of samples in different groups are significantly 
different from each other by statistical analysis (two-way ANOVA). 
 
Figure 15. RhoA and Rac1 activity upon graded ATP-depletion 
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Fig. 15A. RhoA activity upon graded ATP-depletion 
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Fig. 15B. Rac1 activity upon graded ATP-depletion 
 
 
Fig. 15. RhoA and Rac1 exhibited intermediate levels of activity at intermediate ATP 
levels upon graded ATP-depletion.  The active GTP-bound RhoA was pulled-down from 
the lysate of S3 cells using glutathione-agarose beads pre-bound with recombinant GST 
fusion protein containing the RhoA binding domain of Rho kinase (which only binds the 
GTP-bound form of RhoA), measured with RhoA antibody, and then normalized against 
the total RhoA in the lysate of S3 cells.  The active GTP-bound Rac1 was pulled-down 
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from the lysate of S3 cells using glutathione-agarose beads pre-bound with recombinant 
GST fusion protein containing the CRIB (GTPase binding-domain) of PAK kinase 
(which binds the GTP-bound form of Rac and Cdc42), measured with Rac1 antibody, and 
then normalized against the total Rac1 in the lysate of S3 cells.  ATP depletion was done 
for 30 minutes.  In each single experiment, the activity of RhoA or Rac1 in all the other 
samples are presented as percentages compared with the sample of normal control.  The 
error bar in the column of normal control shows the standard deviation of RhoA or Rac1 
activity around the average of 4 experiment repeats.  The underlines (A, B, and C) are 
used to group samples.  The data values of samples in different groups are significantly 
different from each other by statisctical analysis (two-way ANOVA). 
 
Activation of AMPK inhibits RhoA activity and changes stress fiber morphology 
In order to investigate whether AMPK activation is upstream of the signaling 
pathways that leads to the inhibition of Rho GTPases activity, we treated S3 cells with 
two different cell-permeable small molecule chemicals, AICAR and metformin, which 
were considered to activate AMPK in vivo by different mechanisms.  We found that both 
AICAR (used at 2mM concentration in normal growth medium of S3 cells for 90 minutes 
continuous treatment) and metformin (used at 10mM concentration in normal growth 
medium of S3 cells for 4 hours continuous treatment) were able to activate AMPK in S3 
cells as indicated by the increase of Thr172 phosphorylation level of the AMPK α subunit.  
Meanwhile, after AICAR activation of AMPK or metformin activation of AMPK, we also 
found that the GTPase activity of RhoA (but not Rac1) decreased as measured by the 
“pull-down” assay of GTP-bound, active RhoA (or Rac1) (Fig. 16 and Fig. 17), although 
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the decrease of the RhoA activity after metformin activation of AMPK was not 
statistically significant, which could be due to the small number of experiment repeats. 
 
Figure 16. AMPK activation by AICAR inhibits RhoA activity, but not Rac1 
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Fig. 16. AICAR treatment of S3 cells under normal growth conditions activated AMPK 
and suppressed RhoA activity, but had no significant effect on Rac1 activity.  AICAR in 
aqueous stock solution was used at 2mM for 90 minutes treatment of S3 cells.  The 
activity of AMPK, RhoA and Rac1 was measured respectively as previously described.  
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In each single experiment, the activity of AMPK, RhoA or Rac1 in all the other samples 
are presented as the ratios compared with the sample of normal control.  The error bar in 
the column of normal control shows the standard deviation of the activity of AMPK, 
RhoA or Rac1 around the average of experiment repeats.  The letters of A and B under 
the column charts label and group samples.  The data values of samples in different 
groups are significantly different from each other by statisctical analysis (two-way 
ANOVA). 
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Figure 17. AMPK activation by metformin may inhibit RhoA activity, but not Rac1 
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Fig. 17. Metformin treatment of S3 cells under normal growth conditions activated 
AMPK and might suppress RhoA activity, but had no significant effect on Rac1 activity.  
Metformin in aqueous stock solution was used at 10mM for 4 hours treatment of S3 cells.  
The activity of AMPK, RhoA and Rac1 was measured respectively as previously 
described.  In each single experiment, the activity of AMPK, RhoA or Rac1 in all the 
other samples are presented as the ratios compared with the sample of normal control.   
The error bar in the column of normal control shows the standard deviation of the activity 
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of AMPK, RhoA or Rac1 around the average of experiment repeats.  The letters of A and 
B under the column charts label and group samples.  The data values of samples in 
different groups are significantly different from each other by statisctical analysis (two-
way ANOVA). 
 
We were also interested in the possible changes of actin cytoskeleton after AMPK 
activation.  We labeled the F-actin in S3 cells with rhodamine-conjugated phalloidin.  The 
results showed that the activation of AMPK with either AICAR or metformin induced 
similar morphological changes of stress fibers in S3 cells.  After treating S3 cells with 
either AICAR or metformin, there was not such a global and total disruption of actin 
cytoskeleton in S3 cells as seen during ATP-depletion, instead the stress fibers appeared 
to be considerably thicker and more bundled in comparison with the control S3 cells 
under normal growth conditions (Fig. 18 and Fig. 19), which indicated that the actin 
cytoskeleton was affected by AMPK activation with AICAR or metformin treatment. 
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Figure 18. AMPK activation by AICAR induced morphological changes of stress 
fibers 
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Fig. 18. AMPK activation by AICAR induced morphological changes of stress fibers in 
S3 cells.  The F-actin in S3 cells were labeled with rhodamine-phalloidin.  The stress 
fibers in S3 cells after 90 minutes treatment with 2mM AICAR (Fig. 18A) appeared to be 
considerably thicker and more bundled in comparison with the control S3 cells (Fig. 18B) 
under normal growth conditions.  C shows S3 cells after 30 minutes ATP-depletion for 
comparison. 
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Figure 19. AMPK activation by metformin induced morphological changes of stress 
fibers 
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Fig. 19. AMPK activation by metformin induced morphological changes of stress fibers 
in S3 cells.  The F-actin in S3 cells were labeled with rhodamine-phalloidin.  The stress 
fibers in S3 cells after 4 hours treatment with 10mM metformin (Fig. 19A) appeared to be 
considerably thicker and more bundled in comparison with the control S3 cells (Fig. 19B) 
under normal growth conditions.  C shows S3 cells after 30 minutes ATP-depletion for 
comparison. 
 
Inhibition of AMPK activation partially rescues stress fibers disruption during ATP-
depletion 
In order to further investigate how the activation of AMPK during ATP-depletion 
affects the Rho GTPases activity and actin cytoskeleton, we utilized the strategy of 
inhibiting AMPK activation during ATP-depletion.  The Compound C, a cell-permeable 
small molecule chemical, is a selective, ATP-competitive inhibitor of AMPK.  It has been 
frequently used to inhibit AMPK activity in previous studies related to AMPK.  We pre-
treated S3 cells with 100µM compound C for 4 hours before ATP-depletion and also 
added 100µM compound C into the medium during ATP-depletion.  We found that the 
treatment with compound C inhibited activation of AMPK during ATP-depletion in S3 
cells, as indicated by the decrease of Thr172 phosphorylation level of AMPK α subunit 
(Fig. 20); although we failed to detect significant change of GTPase activity of either 
RhoA or Rac1 as measured by the “pull-down” assay of GTP-bound, active RhoA (or 
Rac1) after inhibition of AMPK activation with compound C during ATP-depletion (data 
not shown here).  However when we labeled the F-actin in S3 cells with rhodamine-
conjugated phalloidin, we found some thin, continuous and longer stress fibers in the S3 
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cells after using compound C to inhibit AMPK activation during ATP-depletion (Fig. 21).  
Such stress fibers exist in S3 cells under normal growth condition, but not in S3 cells 
with severe actin cytoskeleton disruptions after ATP-depletion.  Therefore our results 
showed that the inhibition of AMPK activation by the compound C treatment during 
ATP-depletion partially rescued the actin cytoskeleton dysregulation during ATP-
depletion. 
 
Figure 20. Compound C inhibited AMPK activation during ATP-depletion 
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Fig. 20. Compound C treatment of S3 cells during ATP-depletion inhibited AMPK 
activation as indicated by the Thr172 phosphorylation level decrease of AMPK α subunit 
in comparison with S3 cells after only regular ATP-depletion or after ATP-depletion with 
DMSO (solvent of compound C) treatment.  Compound C in DMSO stock solution was 
used at 100μM for 4 hours treatment of S3 cells immediately before ATP-depletion and 
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also used at 100μM during 30 minutes ATP-depletion.  DMSO was used at 1% under the 
same treatment conditions as a control of compound C.  In each single experiment, the 
activity of AMPK in all the other samples are presented as percentages compared with the 
sample of 1% DMSO treatment.  The error bar in the column of 1% DMSO treatment 
shows the standard deviation of the activity of AMPK around the average of 3 experiment 
repeats.  The letters of A and B under the column chart label and group samples.  The 
data values of samples in different groups are significantly different from each other by 
statisctical analysis (two-way ANOVA). 
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Figure 21. Inhibition of AMPK activation partially rescued stress fiber disruption 
during ATP-depletion 
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Fig. 21. The F-actin in S3 cells were labeled with rhodamine-phalloidin after different 
treatments.  Some thin, continuous and longer stress fibers existed in the S3 cells after 
ATP-depletion with inhibition of AMPK activation by the compound C treatment (Fig. 
21A), but not in either the S3 cells after only regular ATP-depletion (Fig. 21B) or after 
ATP-depletion with DMSO (solvent of Compound C) (Fig. 21C) treatment.  Fig. 21D 
shows the F-actin staining (mostly stress fibers) in the S3 cells under normal growth 
conditions. 
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4.  Discussion 
Rho GTPases play a critical role in the regulation of actin cytoskeleton.  In our 
previous study, we found that in kidney epithelial cells the activity of Rac and RhoA but 
not Cdc42 significantly and also very quickly decreased with ATP-depletion/ischemia.  
The GTP level decrease during ATP-depletion cannot fully explain the GTPase activity 
decrease of Rho and Rac, because the GTP level is still considerably higher than the Km 
for GTP of Rho and Rac during ATP-depletion [160], and also because the rate of RhoA 
inactivation during ischemia/ATP-depletion is so rapid that it cannot be explained by the 
intrinsic rate of nucleotide exchange or hydrolysis.  Taken together, these point to 
upstream signaling pathways which are activated or inactivated during ischemia and lead 
to the downregulation of Rho GTPases activity.  In this study we propose these signaling 
pathways are initiated through the activation of the ultra-sensitive cellular energy sensor 
AMP-activated protein kinase (AMPK).  We found that within 5 minutes of ATP-
depletion AMPK was strongly activated, which suggested that AMPK was extremely 
sensitive to the energy level change in kidney epithelial cells. 
Since the ATP-depletion was achieved by antimycin A treatment of S3 cells in 
serum-free substrate-depleted medium, we tested whether AMPK responded to different 
ATP and energy levels, and if the rapid activation of AMPK during ATP-depletion was 
due to the antimycin A treatment instead.  By supplementing the medium with different 
concentrations of glucose (500-2000mg/L) during ATP-depletion, we were able to induce 
intermediate ATP and energy levels (between the levels after regular ATP-depletion and 
under normal growth conditions).  Even though the activity level of AMPK after ATP-
depletion with lower concentrations of glucose supplementation did not appear to be 
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significantly different from after regular ATP-depletion with no glucose supplementation, 
we did find that the AMPK activity decreased when the glucose concentration increased 
with the overall energy/ATP level (as measured with HPLC) being closer to the level 
under normal growth conditions.  The “pull-down” assays of GTP-bound active RhoA 
and Rac1 showed that they also exhibited intermediate levels of GTPase activity upon 
glucose supplementation.  At lower concentrations of glucose supplementation, the 
activity of RhoA and Rac1 was still higher than after regular ATP-depletion without 
glucose supplementation.  This may suggest that when the severity of ischemia and ATP-
depletion reaches a certain level, upstream regulators other than AMPK further contribute 
to the inactivation of Rho GTPases.  Overall these results confirm a correlation among 
energy/ATP level decrease, AMPK activation and Rho GTPases inactivation during ATP-
depletion in kidney epithelial cells. 
To further investigate the relationship between activation of AMPK and Rho 
GTPases inactivation, we attempted to manipulate the AMPK activity in S3 cells and 
expected to find a subsequent effect on Rho GTPases activity.  AICAR and metformin are 
two drugs widely-used to activate AMPK in previous studies.  The mechanism of 
metformin activating AMPK is still unclear.  There was a report that metformin increased 
the cytosolic concentration of AMP in the heart, and therefore activated AMPK [161].  
AICAR is metabolized into ZMP in cells, which is an AMP analogue and activates 
AMPK.  After the treatment of S3 cells with either metformin or AICAR, there was an 
activation of AMPK as shown by the increase in Thr172 phosphorylation level of AMPK 
α subunit.  We also detected a decrease of RhoA activity in S3 cells after treatment with 
AICAR and also after treatment with metformin (although the latter difference was not 
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statistically significant), in comparison with S3 cells under only normal growth 
conditions.  Although there was a report showing that AMPK activation affected Rac1 
activity in muscle cells [162], we did not find significant change of Rac1 activity upon 
AMPK activation by metformin or AICAR.  This could be due to the activation of AMPK 
by these two drugs still not being strong enough to affect Rac1 activity in S3 epithelial 
cells, or possibly because other signaling pathways make major contributions to the 
inactivation of Rac1 during ATP-depletion and ischemia.  When we treated S3 cells with 
either AICAR or metformin, we found that the stress fibers in S3 cells were considerably 
thicker and more bundled than under normal growth conditions.  These results were 
different from our initial expectations since we expected that after AMPK activation and 
partial inhibition of RhoA activity with these drug treatments, the actin cytoskeleton 
would be dysregulated and exhibit morphology more resembling that after ATP-depletion.  
It is possible that in addition to AMPK activation, AICAR and metformin also affect 
other signaling pathways which have stronger effects on actin cytoskeleton and lead to 
these morphological changes.  These findings indicate that AMPK activation does affect 
Rho GTPase signaling pathways and actin cytoskeleton, but the real mechanisms are 
more complex than our initial hypothesis, particularly in terms of its effect on the actin 
cytoskeleton. 
In addition to activating AMPK with metformin and AICAR, we treated S3 cells 
with another drug, compound C which enabled us to inhibit partially the activation of 
AMPK caused by ATP-depletion.  Such an inhibition partially rescued the drastic stress 
fibers disruption caused by ATP-depletion, but we did not find significant change of 
RhoA or Rac1 activity at the same time.  One possible explanation is that the changes of 
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RhoA and/or Rac1 activity upon compound C treatment during ATP-depletion localized 
at the actin cytoskeleton and these fractions of RhoA and/or Rac1 were not fully 
recovered by the lysis buffer; therefore we were unable to detect the actual changes. 
In addition to activating AMPK with metformin and AICAR, we also attempted to 
express different types of AMPK mutants (dominant negative mutant, constitutively 
active mutant, etc.) in S3 cells by transient transfection of plasmids encoding these 
mutants.  For some unclear reasons, the transfection of these plasmids was not successful.  
We also attempted to manipulate AMPK activity in S3 cells by knocking down AMPK 
expression with siRNA targeting against the AMPK α subunit.  After transfection of such 
siRNA into S3 cells, we were able to knock down the expression of AMPK α subunit by 
60-70%, and there was a similar extent of AMPK activity decrease (as shown by the 
decrease of Thr172 phosphorylation level of AMPK α subunit) during ATP-depletion in 
these S3 cells with siRNA transfection.  However we did not detect a significant change 
of either RhoA or Rac1 activity in the same experiment.  Possibly the more significant 
knockdown of AMPK expression is necessary to induce the reversal of Rho GTPases 
inactivation during ATP-depletion and ischemia.  In the future, we would like to construct 
lentiviral vectors or other viral vectors encoding different types of AMPK mutants or 
shRNA against AMPK α subunit in order to manipulate AMPK activity more 
significantly.  Stronger changes of AMPK activity than what we have been able to 
achieve by drug treatment or SiRNA knock-down will probably enable us to investigate 
more informatively the relationship between AMPK activation and Rho GTPases 
inactivation. 
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In this study, we propose that ATP-depletion and ischemia activates AMPK which 
further depresses the activity of signaling pathways through TSC1/2, Rheb GTPase and 
mTOR kinase in mTOR complex, leading to disrupted Rho GTPase activity and 
eventually cytoskeletal dysregulation.  There was also a study suggesting that 
independently from mTOR complex pathway, TSC1 inhibits Rac1 activity and activates 
Rho activity through the antagonism between Rac1 and Rho, and this effect of TSC1 is 
blocked upon TSC2 binding to form TSC1/2 complex [163]. 
Since the mTOR kinase exists in vivo in both mTOR complex 1 and mTOR 
complex 2 that have different components, the question arises as to which mTOR 
complex plays the major role in the signaling pathways proposed by us.  Although mTOR 
complex 2 has been deemed to be an actin cytoskeleton regulator, and it may signal to 
actin cytoskeleton through Rho and Rac [151]; there has not been any evidence showing 
that its activity is regulated by Rheb GTPase as mTOR complex 1 is.  A recent study 
actually suggested that TSC1/2 complex physically associated with mTOR complex 2 
and was required for the proper activation of mTOR complex 2 kinase activity [164].  
The same study also suggested that the ability of TSC1/2 complex to promote mTOR 
complex 2 kinase activity was separate from its GAP activity toward Rheb GTPase.  
Meanwhile some recent studies have confirmed that the kinase activity of mTOR 
complex 1 is indeed involved in the regulation of actin cytoskeleton [152, 153].  Another 
recent study showed that AMPK inhibited the kinase activity of mTOR complex 1 by 
phosphorylating one of its components, Raptor, directly [144].  Therefore it is highly 
possible that it is mTOR complex 1 instead of mTOR complex 2 that is directly involved 
in the signaling pathways from AMPK activation to Rho GTPases inactivation during 
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ATP-depletion and ischemia as proposed by us.  As for the effect of mTOR complex 2 
kinase activity on actin cytoskeleton regulation, it could be indirect through mTOR 
complex 1.  MTOR complex 2 has been found to phosphorylate Ser473 of Akt/protein 
kinase B (PKB), which is critical for the activation of Akt/PKB [165, 166].  Akt/PKB 
directly phosphorylates TSC2 in TSC1/2 complex on multiple sites, and this 
phosphorylation inhibits the GAP activity of TSC1/2 complex, thus upregulating mTOR 
complex 1 activity.  Akt/PKB can also phosphorylate PRAS40 (proline-rich Akt substrate 
40 kDa) and this phosphorylation appears to release the inhibition of PRAS40 on kinase 
activity of mTOR complex1 possibly by disrupting its binding with mTOR complex 1 
(whether it is a component of mTOR complex 1 remains to be determined) [167, 168].  
Therefore the inactivation of mTOR complex 2 could lead to the inhibition of mTOR 
complex 1 through Akt/PKB with further downstream effects on Rho GTPases and actin 
cytoskeleton. 
In order to determine which mTOR complex is involved in the signaling pathways 
that we proposed, one possible strategy in our future work will be to treat S3 cells with 
rapamycin and investigate the possible Rho GTPases activity changes and actin 
cytoskeleton disruptions since mTOR complex 2 is not sensitive to rapamycin (or at least 
not responding to acute rapamycin treatment as significantly as mTOR complex 1).  We 
might also knock down the protein expression of Raptor (which is the component of 
mTOR complex 1 but not mTOR complex 2) with SiRNA as another strategy to resolve 
the question of “1 or 2”. 
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5.  Summary 
The dysregulation of Rho GTPase signaling pathways is a critical mediator of the 
effects of ATP depletion and ischemia on the actin cytoskeleton, but the mechanism by 
which ATP depletion leads to altered RhoA and Rac1 activity is unknown.  The AMP-
activated protein kinase (AMPK) is a key metabolic regulator that senses the cellular 
ATP/AMP ratio. Renal ischemia in vivo has been shown to activate AMPK.  We propose 
that ischemia and ATP depletion result in activation of AMPK and that this affects Rho 
GTPase activity and cytoskeletal organization (possibly via TSC1/2 complex and/or 
mTOR complex).  To test this hypothesis we used S3 epithelial cells derived from the 
proximal tubule in mouse kidney in a cell culture model of renal ischemia using 
antimycin A and substrate depletion to induce ATP depletion. We used the 
phosphorylation of Thr172 of the AMPK α-subunit as a measure of AMPK activation, 
and also used pull-down assays to measure the GTPase activity of RhoA and Rac1 
proteins.  AMPK was rapidly activated (≤ 5 minutes) by ATP depletion, and there was a 
corresponding decrease in RhoA and Rac1 activity.  We used graded concentrations of 
glucose in the nutrient-depleted growth medium containing antimycin A to achieve 
intermediate levels of ATP depletion, confirmed by HPLC analysis.  We found 
intermediate levels of AMPK activity at these intermediate ATP levels while the activity 
of both RhoA and Rac1 correlated inversely with the activity of AMPK.  AICAR or 
metformin treatment activated AMPK in S3 cells, and the RhoA activity was suppressed 
by AICAR or metformin activation of AMPK.  This is consistent with our hypothesis.  
Meanwhile after either AICAR or metformin treatment the stress fibers of S3 cells 
exhibited morphological changes.  We also found that treating S3 cells with the AMPK 
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inhibitor, compound C continuously before and during ATP-depletion partially inhibited 
the activation of AMPK caused by ATP-depletion, and also partially rescued the 
disruptions of stress fibers caused by ATP-depletion.  Therefore our data support the 
hypothesis that the activation of AMPK is at the upstream of the signaling pathways 
downregulating RhoA activity during ATP depletion that eventually leads to the actin 
cytoskeletal disruptions.  Further studies will be needed to elucidate the intermediary 
signaling pathways between AMPK activation and RhoA inactivation during kidney 
ischemia, which could be via TSC1/2 complex activation and/or Rheb GTPase 
inactivation leading to mTOR complex 1 kinase activity inhibition. 
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